Our previous studies also showed that metformin could enhance EGFR-TKI sensitivity in EGFR-TKI resistant NSCLC cells [21], metformin use was associated with improved survival and delayed onset of acquired resistance to EGFR-TKI in patients with NSCLC and diabetes mellitus type 2 [22]. The gene discussed is EGFR; the disease is type 2 diabetes mellitus.